
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function, focusing on myelination, oligodendrocyte lineage, and neuronal/glial features.<br><br>**Myelin / lipid metabolism / oligodendrocyte function**<br>- **MOG** ‚Äì Myelin oligodendrocyte glycoprotein; classic compact myelin protein, highly specific to mature myelinating oligodendrocytes.<br>- **MAG** ‚Äì Myelin-associated glycoprotein; paranodal myelin protein, expressed in myelinating oligodendrocytes.<br>- **PLP1** ‚Äì Proteolipid protein 1; major CNS myelin protein, hallmark of oligodendrocytes.<br>- **MOBP** (not listed) / **ERMN** ‚Äì Ermin; cytoskeletal protein enriched in myelinating oligodendrocytes, involved in myelin sheath formation.<br>- **UGT8** ‚Äì UDP glycosyltransferase 8; catalyzes galactosylceramide synthesis, critical for myelin lipid biosynthesis.<br>- **FA2H** ‚Äì Fatty acid 2-hydroxylase; involved in synthesis of 2-hydroxylated sphingolipids, important for myelin stability.<br>- **TPPP** ‚Äì Tubulin polymerization-promoting protein; enriched in oligodendrocytes, associated with microtubule dynamics in myelinating cells.<br>- **CNDP1** ‚Äì Carnosine dipeptidase 1; expressed in oligodendrocytes in several human brain sc/snRNA-seq datasets, linked to metabolic support.<br>- **CARNS1** ‚Äì Carnosine synthase; also seen in oligodendrocyte/myelinating populations, involved in histidine-containing dipeptide metabolism.<br>- **HEPACAM** ‚Äì Hepatocyte cell adhesion molecule; strong marker of oligodendrocyte lineage (especially OPCs and some OLs) in human brain, involved in cell adhesion and blood‚Äìbrain barrier/astroglial interfaces but also robust in OL lineage clusters.<br>- **GJB1** ‚Äì Connexin 32; gap junction protein in oligodendrocytes and Schwann cells, mediating oligodendrocyte‚Äìastrocyte coupling.<br>- **SLC24A2** ‚Äì Na+/Ca2+-K+ exchanger; enriched in oligodendrocytes/myelinating cells in human datasets, involved in ion homeostasis.<br>- **SLC5A11** ‚Äì Sodium-dependent myo-inositol transporter; expressed in oligodendrocytes and involved in osmolyte/inositol transport.<br>- **SLCO1A2** ‚Äì Organic anion transporter; enriched in oligodendrocyte/BBB-related populations in human brain, involved in solute transport.<br>- **TF** ‚Äì Transferrin; iron transport protein, strongly expressed in oligodendrocytes (iron-demanding myelinating cells).<br>- **ATP10B** ‚Äì P4-ATPase (phospholipid flippase); implicated in phospholipid translocation, consistent with high membrane turnover in myelinating cells.<br>- **OMG** ‚Äì Oligodendrocyte myelin glycoprotein; myelin-associated inhibitor of neurite outgrowth, oligodendrocyte/myelin-specific.<br><br>**Transcription factors / lineage regulators**<br>- **SOX10** ‚Äì Master regulator of oligodendrocyte lineage; required for OL differentiation and myelin gene expression.<br>- **OLIG2** ‚Äì Basic helix-loop-helix TF; canonical oligodendrocyte lineage marker (also in some ventral progenitors), persists in OLs.<br>- **NKX6-2** ‚Äì Homeobox TF; enriched in oligodendrocyte lineage, particularly in differentiating and mature OLs in human cortex.<br>- **ST18** ‚Äì Transcription factor enriched in subsets of oligodendrocytes and some neuronal populations; in human brain snRNA-seq, often marks specific OL subclusters.<br><br>**Cytoskeleton / process extension / maturation**<br>- **TUBB4A** ‚Äì Œ≤-tubulin isoform; enriched in oligodendrocytes and some neurons, associated with myelinating OLs in human datasets.<br>- **DPYSL5 (CRMP5)** ‚Äì Collapsin response mediator protein; involved in neurite outgrowth and process extension, expressed in OL lineage and neurons.<br>- **STMN4** ‚Äì Stathmin family; microtubule dynamics, often higher in more immature/differentiating OLs compared to fully mature ones.<br><br>**Cell adhesion / axon‚Äìglia interaction**<br>- **CNTN2 (TAG-1)** ‚Äì Contactin 2; axon‚Äìglia adhesion molecule at juxtaparanodes, expressed in both neurons and oligodendrocytes; in OLs, associated with myelinated axons.<br>- **CADM2** ‚Äì Cell adhesion molecule 2; neuronal/axon-associated, but also appears in OL clusters that interact with specific axon types.<br>- **CNTNAP4** ‚Äì Neurexin family; typically neuronal, but low-level expression can appear in OLs in some datasets, reflecting axon-associated transcriptional programs.<br>- **AMER2 (FAM123C)** ‚Äì Microtubule-binding protein enriched in OLs and some neurons; associated with Wnt signaling modulation and cytoskeletal organization.<br><br>**Ion channels / transporters**<br>- **KCNJ10 (Kir4.1)** ‚Äì Inward-rectifier K+ channel; classically astrocytic, but in human data can be expressed in some OL lineage cells, especially perivascular/ion-buffering OLs.<br>- **SLC24A2, SLC5A11, SLCO1A2** ‚Äì As above, ion/solute transporters consistent with glial homeostatic roles.<br><br>**Neuronal-associated genes (contextual, not dominant)**<br>- **GRIA2** ‚Äì AMPA receptor subunit; strongly neuronal, but low-level expression is common in OLs (glutamate responsiveness).<br>- **ELAVL3** ‚Äì Neuronal RNA-binding protein (HuC); typically neuronal, but low expression can appear in OL clusters in some human datasets, especially in transitional states or due to ambient RNA.<br>- **PRIMA1** ‚Äì Anchors acetylcholinesterase at neuronal membranes; mostly neuronal, but again can be low-level or ambient.<br><br>**Other / lncRNAs / less characterized**<br>- **VSTM2B, KLK6, PLPPR1, SEC14L5, TMEM151A, SPOCK3, KLHL32, LRP2, HEPACAM, AC* / AL* lncRNAs, NTM-AS1, LINC00320, HEPN1, OR7A5** ‚Äì Many of these are known from human brain snRNA-seq as enriched in specific oligodendrocyte subclusters (e.g., KLK6, SPOCK3, PLPPR1, VSTM2B) or in glial/BBB-related populations (LRP2, HEPACAM). KLK6 in particular is a well-known marker of certain mature OL states and reactive OLs.<br><br>2. Key cell type markers (by tissue/cell class)<br><br>**Canonical oligodendrocyte / myelinating OL markers**<br>- **PLP1, MOG, MAG, OMG, UGT8, FA2H, TF, ERMN, TPPP, GJB1, SLC24A2, SLC5A11, SLCO1A2, HEPACAM, CNDP1, CARNS1, VSTM2B, KLK6, PLPPR1, SPOCK3**<br>  - This combination is highly characteristic of **mature, myelinating oligodendrocytes** in human cortex/white matter.<br><br>**Oligodendrocyte lineage TFs**<br>- **SOX10, OLIG2, NKX6-2, ST18**<br>  - Strongly support oligodendrocyte lineage identity rather than astrocyte or neuron.<br><br>**OPC vs mature OL discrimination**<br>- OPC markers (e.g., PDGFRA, CSPG4/NG2, VCAN, PDGFRB) are **absent** from the list.<br>- Instead, we see high expression of **MOG, MAG, PLP1, ERMN, UGT8, FA2H, TF**, which are **late-stage myelinating OL** markers.<br>- Presence of **STMN4, DPYSL5** suggests some dynamic cytoskeletal remodeling, but in the context of strong myelin gene expression, this is more consistent with **differentiating to mature OLs** rather than early OPCs.<br><br>**Astrocyte markers**<br>- Classic astrocyte markers (GFAP, AQP4, ALDH1L1, SLC1A3/GLAST, SLC1A2/EAAT2) are not present.<br>- **KCNJ10** is astrocyte-enriched but not exclusive; in human data, some OL subtypes express it, especially those with perivascular/ion-buffering roles.<br><br>**Neuronal markers**<br>- **GRIA2, ELAVL3, PRIMA1, CADM2, CNTNAP4** are neuronal, but:<br>  - They are not accompanied by a broad neuronal program (no NEUN/RBFOX3, SYT1, SNAP25, MAP2, etc.).<br>  - In human snRNA-seq, low-level neuronal gene expression is common in OL clusters, likely reflecting axon‚Äìglia signaling or ambient RNA.<br><br>3. Cross-referencing with known scRNA/snRNA-seq atlases and literature<br><br>Using major human brain atlases (e.g., Lake et al. 2018; Hodge et al. 2019; J√§kel et al. 2019; Siletti et al. 2023; Allen Brain Map human MTG/cortex datasets; NeMO/CellxGene OL annotations):<br><br>- **Core OL identity**:<br>  - Co-expression of **PLP1, MOG, MAG, ERMN, UGT8, FA2H, TF, GJB1, TPPP, SOX10, OLIG2, NKX6-2** is the canonical signature of **mature oligodendrocytes**.<br>  - These genes define OL clusters such as ‚ÄúOligo_1‚Äì6‚Äù, ‚ÄúOL1‚ÄìOL6‚Äù, ‚ÄúMature OL‚Äù, ‚ÄúMyelinating OL‚Äù in multiple datasets.<br><br>- **Subcluster-specific markers**:<br>  - **KLK6, VSTM2B, SPOCK3, PLPPR1, CNDP1, CARNS1, SLC24A2, SLCO1A2, SLC5A11, HEPACAM** are repeatedly seen as **subtype markers** for distinct mature OL states in human cortex and white matter.<br>  - For example, J√§kel et al. (2019, Nature) and subsequent human studies identify OL subtypes like:<br>    - **OL1/‚ÄúMature myelinating‚Äù**: high PLP1, MOG, MAG, ERMN, UGT8, FA2H.<br>    - **OL2/‚ÄúNewly formed‚Äù**: lower MOG, higher genes like STMN4, DPYSL family.<br>    - **OL3‚ÄìOL6**: enriched for KLK6, VSTM2B, SPOCK3, CNDP1, CARNS1, etc., often associated with region-specific or activity-dependent myelination.<br>  - **KLK6** is particularly associated with **late, often white-matter-enriched OLs** and sometimes with disease/reactive OL states.<br><br>- **Exclusion of other glia**:<br>  - Lack of astrocyte, microglia, endothelial, or pericyte canonical markers strongly argues against those identities.<br><br>4. Most probable general cell type<br><br>Given the dominance of myelin structural genes, OL lineage TFs, and OL-specific metabolic/transport genes, the general cell type is:<br><br>**General cell type: Oligodendrocyte (mature, myelinating)**<br><br>5. Top 3 most probable sub cell types (ranked) and final subtype call<br><br>Within oligodendrocytes, human datasets typically distinguish:<br><br>- OPCs / committed OPCs<br>- Newly formed / early differentiating OLs<br>- Intermediate / pre-myelinating OLs<br>- Mature myelinating OLs<br>- Region- or state-specific mature OL subtypes (e.g., KLK6+, VSTM2B+, SPOCK3+ OLs)<br><br>Key discriminants in your list:<br><br>- Strong **myelin structural program**: **MOG, MAG, PLP1, ERMN, UGT8, FA2H, TF, GJB1, TPPP** ‚Üí clearly **post-mitotic, myelinating**.<br>- Presence of **KLK6, VSTM2B, SPOCK3, PLPPR1, CNDP1, CARNS1, SLC24A2, SLCO1A2, SLC5A11** ‚Üí characteristic of **specific mature OL subclusters** in human cortex/white matter, often labeled ‚ÄúOL5/OL6‚Äù, ‚ÄúOligo_5/6‚Äù, or ‚ÄúKLK6+/VSTM2B+ OL‚Äù.<br>- Some **STMN4, DPYSL5** suggests not the very terminally quiescent OL, but still clearly beyond OPC.<br><br>**Ranked subtypes:**<br><br>1. **Most likely: Mature myelinating oligodendrocyte ‚Äì KLK6+/VSTM2B+/SPOCK3+ subtype (late-stage OL, often white-matter-enriched)**  <br>   - Justification:<br>     - High **MOG, MAG, PLP1, ERMN, UGT8, FA2H, TF** ‚Üí fully myelinating.<br>     - **KLK6, VSTM2B, SPOCK3, PLPPR1, CNDP1, CARNS1, SLC24A2, SLCO1A2, SLC5A11** match the transcriptional profile of **late, specialized OL subclusters** in human atlases.<br>     - **SOX10, OLIG2, NKX6-2** confirm lineage; absence of OPC markers rules out progenitors.<br><br>2. **Second: Mature myelinating oligodendrocyte ‚Äì general cortical/white-matter OL (non-specifically subtyped)**  <br>   - If one does not distinguish KLK6+/VSTM2B+ subclusters, this would be annotated simply as **‚ÄúMature myelinating oligodendrocyte‚Äù**.<br>   - Fits all canonical markers but ignores finer subtype resolution.<br><br>3. **Third: Differentiating / newly formed oligodendrocyte (transitioning to myelinating)**  <br>   - Supported weakly by **STMN4, DPYSL5**, which are higher in earlier OL states.<br>   - However, the very strong myelin gene expression and presence of late markers (KLK6, VSTM2B, SPOCK3) make this less likely than a fully mature subtype.<br><br>**Most likely subtype (final call):**  <br>**Mature myelinating oligodendrocyte, KLK6+/VSTM2B+/SPOCK3+ late-stage subtype (human cortical/white-matter OL).**<br><br>6. Concise summary<br><br>- The marker set is dominated by **myelin structural genes (PLP1, MOG, MAG, ERMN, OMG)**, **myelin lipid metabolism genes (UGT8, FA2H)**, **oligodendrocyte lineage TFs (SOX10, OLIG2, NKX6-2)**, and **OL-enriched transport/metabolic genes (TF, GJB1, SLC24A2, SLC5A11, SLCO1A2, CNDP1, CARNS1)**.  <br>- Absence of OPC, astrocyte, microglial, or neuronal core programs, plus presence of **KLK6, VSTM2B, SPOCK3, PLPPR1**, matches **late, mature myelinating oligodendrocyte subclusters** described in human brain sc/snRNA-seq atlases.  <br>- Therefore, this cluster is best annotated as a **mature myelinating oligodendrocyte**, specifically a **KLK6+/VSTM2B+/SPOCK3+ late-stage OL subtype**.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Mature myelinating oligodendrocyte</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Mature myelinating oligodendrocyte ‚Äì KLK6+/VSTM2B+/SPOCK3+ late-stage subtype (human cortical/white-matter OL)</li><li>Mature myelinating oligodendrocyte ‚Äì general cortical/white-matter OL (non-specifically subtyped)</li><li>Differentiating/newly formed oligodendrocyte transitioning to myelinating state</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Oligodendrocyte with low-level neuronal-associated gene expression (GRIA2, ELAVL3, PRIMA1, CADM2, CNTNAP4) likely due to axon‚Äìglia interaction or ambient RNA</li><li>Oligodendrocyte subtype with partial astrocyte-like ion-buffering features (KCNJ10-expressing OLs)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    